Objective: We sought to investigate the relationship between prepregnancy weight, treatment modality (diet or insulin), level of glycemic control, and pregnancy outcome.
Study Design: We recruited women with gestational diabetes (GDM) from inner city prenatal clinics. All women were instructed in the use of an intensified management protocol using memory reflectance meters. Outcomes were analyzed according to maternal prepregnancy body mass index (BMI, kg/m 2 ) categories: normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), and obese (BMI > or =30), and by diet or insulin therapy and glycemic control (mean blood glucose <100 mg/dL = good control). Pregnancy outcome variables included a composite outcome (at least 1 of the following: neonatal metabolic complications, large-for-gestational age or macrosomic infants, NICU admission for >24 hours, and the need for respiratory support) (not including oxygen therapy). In addition to composite outcome, a bivariate analysis was performed for each single variable, including preeclampsia and cesarean section delivery.
Results: Four thousand and one women were enrolled. Obese women who achieved targeted levels of glycemic control had comparable pregnancy outcomes to normal weight and overweight women only when they were treated with insulin. Normal weight women treated with diet therapy who achieved targeted levels of glycemic control had good outcomes, but obese women treated with diet therapy who achieved targeted levels of glycemic control, nevertheless, had a 2- to 3-fold higher risk for adverse pregnancy outcome when compared with overweight and normal weight patients with well-controlled GDM. Women with GDM who failed to achieve established levels of glycemic control had significantly higher adverse pregnancy outcomes in all 3 maternal weight groups.
Conclusion: In obese women with BMI > or =30 with GDM, achievement of targeted levels of glycemic control was associated with enhanced outcome only in women treated with insulin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajog.2004.12.049 | DOI Listing |
Perit Dial Int
January 2025
Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).
View Article and Find Full Text PDFCureus
December 2024
Department of Pain Medicine, Fondazione Paolo Procacci, Rome, ITA.
Obesity and type 2 diabetes mellitus (T2DM) are chronic diseases with increasing prevalence, underscoring the urgent need for effective treatment and management strategies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an essential class of drugs for managing both obesity and T2DM, offering additional benefits for cardiovascular and kidney health. GLP-1 RAs work by targeting GLP-1 receptors, mimicking the effects of the natural hormone GLP-1 to regulate blood glucose levels, promote weight loss, and provide potential benefits for cardiovascular health.
View Article and Find Full Text PDFJuntendo Iji Zasshi
December 2024
Diabetes mellitus, characterized by high blood glucose due to inadequate insulin action, comprises two main types: type 1, an autoimmune disease, and type 2, marked by insulin resistance. This review provides a comprehensive overview of diabetes management and treatment advancements. Effective diabetes management includes maintaining blood glucose levels within normal ranges and monitoring HbA1c, a marker reflecting average glucose levels over the past few months.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2025
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, Guangdong Province, China.
Background: Type II diabetes mellitus (T2DM) has been associated with increased risk of colon cancer (CC) and worse prognosis in patients with metastases. The effects of T2DM on postoperative chemoresistance rate (CRR) and long-term disease-free survival (DFS) and overall survival (OS) in patients with stage III CC who receive curative resection remain controversial.
Aim: To investigate whether T2DM or glycemic control is associated with worse postoperative survival outcomes in stage III CC.
Br J Biomed Sci
January 2025
Viollier AG, Allschwil, Switzerland.
Hemoglobin A is a widely used diagnostic tool for monitoring glycemic control in diabetes management. However, its accuracy can be influenced by various factors. We present a case of a 17-year-old boy with abnormally low Hemoglobin A levels caused by warm autoantibody-induced hemolytic anemia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!